Eosinophils are myeloid cells recognized to play a pivotal role as pro-inflammatory or cytotoxic effector cells in a wide variety of diseases of allergic, parasitic, neoplastic, and idiopathic origins. The proliferation and differentiation of these granulocytes in the bone marrow, and their post-mitotic functional maturation and activation in tissues occurs in response to a variety of growth factors and cytokines including GM-CSF, IL-3 and EL-5. While GM-CSF and IL-3 are responsible in part for the lineage commitment of granulocyte progenitors, including priming for certain eosinophil responses such as oxidative burst, lipid and protein mediator release, IL-5 is specifically involved in the differentiation and functional activation of eosinophils; all three cytokines support prolonged eosinophil survival and the development of an activated phenotype in vitro.
Our specific aims are to investigate the mechanisms for molecular regulation of eosinophil genes in response to cytokine (IL3, IL-5) and growth factor (GM-CSF) mediated stimulation of normal eosinophil differentiation and post-mitotic functional activation. Using cDNA and genomic clones we have available for the eosinophil granule proteins including eosinophil cationic protein (ECP), eosinophil-derived neurotoxin (EDN), major basic protein (MBP), eosinophil peroxidase (EPO) and Charcot-Leyden crystal (CLC) protein, we will initially define the most appropriate eosinophil gene for study (i.e. the most eosinophil-specific and/or transcriptionally upregulated). We will focus on the regulation of only one or two genes in inducible eosinophil-committed leukemic cell lines, cytokine-driven differentiation of normal bone marrow or umbilical cord blood-derived progenitors, and cytokine priming/activation of eosinophils from the peripheral blood of normal donors or patients with eosinophilia. The objectives of this proposal are to use studies of eosinophil gene regulation to understand the processes involved in eosinophil lineage commitment, differentiation and priming/activation in response to specific cytokines and growth factors, and ultimately to identify eosinophil-specific transcription factors. The proposed research will address the following questions: 1) What are the mechanisms for the upregulation of the eosinophil granule protein genes? 2) What are the promoters and regulatory elements of eosinophil granule protein genes? 3) What changes in DNAse hypersensitivity are observed in these genes in myeloid (eosinophil) and non-myeloid cells and how are these changes cor-related with alterations in the expression of mRNA during the course of eosinophil differentiation or post-mitotic activation in response to specific cytokines? 4) What are the cis-acting DNA transcriptional control elements responsible for high level expression of eosinophil-specific genes during cytokine-induced differentiation or cell activation? 5) What are the constitutive or cytokine-induced transcription factors which may react with these control elements to regulate eosinophil gene expression? The proposed studies aim to provide a more integrated understanding of the molecular basis for the complex cytokine and growth factor-mediated processes that occur both during normal eosinophil differentiation and the functional activation of eosinophils in tissues in human disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI033043-03
Application #
2068005
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1992-06-01
Project End
1997-04-30
Budget Start
1994-05-01
Budget End
1995-04-30
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Zhenbo; Gu, Xiaorong; Baraoidan, Kristine et al. (2011) RUNX1 regulates corepressor interactions of PU.1. Blood 117:6498-508
Ellis, Anne K; Ackerman, Steven J; Crawford, Lynn et al. (2010) Cord blood molecular biomarkers of eosinophilopoiesis: kinetic analysis of GATA-1, MBP1 and IL-5R alpha mRNA expression. Pediatr Allergy Immunol 21:640-8
Bedi, Richa; Du, Jian; Sharma, Arun K et al. (2009) Human C/EBP-epsilon activator and repressor isoforms differentially reprogram myeloid lineage commitment and differentiation. Blood 113:317-27
Lee, James J; Dimina, Dawn; Macias, MiMi P et al. (2004) Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305:1773-6
Du, Jian; Stankiewicz, Monika J; Liu, Yang et al. (2002) Novel combinatorial interactions of GATA-1, PU.1, and C/EBPepsilon isoforms regulate transcription of the gene encoding eosinophil granule major basic protein. J Biol Chem 277:43481-94
Paul, C C; Aly, E; Lehman, J A et al. (2000) Human cell line that differentiates to all myeloid lineages and expresses neutrophil secondary granule genes. Exp Hematol 28:1373-80
Du, J; Alsayed, Y M; Xin, F et al. (2000) Engagement of the CrkL adapter in interleukin-5 signaling in eosinophils. J Biol Chem 275:33167-75
Yamaguchi, Y; Nishio, H; Kishi, K et al. (1999) C/EBPbeta and GATA-1 synergistically regulate activity of the eosinophil granule major basic protein promoter: implication for C/EBPbeta activity in eosinophil gene expression. Blood 94:1429-39
Yamaguchi, Y; Ackerman, S J; Minegishi, N et al. (1998) Mechanisms of transcription in eosinophils: GATA-1, but not GATA-2, transactivates the promoter of the eosinophil granule major basic protein gene. Blood 91:3447-58
Yamaguchi, Y; Nishio, H; Kasahara, T et al. (1998) Models of lineage switching in hematopoietic development: a new myeloid-committed eosinophil cell line (YJ) demonstrates trilineage potential. Leukemia 12:1430-9

Showing the most recent 10 out of 16 publications